Skip to main content
Clinical Trials/NCT05846035
NCT05846035RecruitingNot Applicable

Paraneoplastic Syndrome in Hepatocellular Carcinoma Patients

Sohag University1 site in 1 country80 target enrollmentStarted: April 15, 2023Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
80
Locations
1
Primary Endpoint
the prevalence of Paraneoplastic Syndrome in cirrhotic Patients with HCC.

Study Overview

Brief Summary

Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world with rising incidence. Globally, there has been substantial variation in prevalence of risk factors for HCC over years, like control of viral hepatitis in developing countries but growing epidemic of fatty liver disease in developed world. Changing epidemiology of HCC is related to trends in these risk factors, Paraneoplastic syndromes (PNS) are defined as systemic, metabolic, or other distant consequences of malignancy resulting, either directly or indirectly, from production by the neoplasm of substances that gain access to the blood stream, thereby exerting their effects on distant organs or tissues There is four major HCC-associated paraneoplastic syndromes among Cirrhotic patients,i.e.hypercholesterolemia,hypoglycemia,hypercalcemia,and erythrocytosis .

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Cross Sectional

Eligibility Criteria

Ages
40 Years to 100 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • - Cirrhotic Patients with HCC.
  • HCC will be diagnosed based on Alpha -feto protein (AFP) and dynamic imaging.

Exclusion Criteria

  • - Patient known to have primary parathyroid disease, patients with bone metastasis or excessive use of antacids.
  • Patients with secondary polycythemia (as chronic hypoxia) and patients with polycythemia rubra vera.
  • Patients with acute infections or GIT bleeding.
  • Patients with preexisting dyslipidemia.
  • Patients with significant cholestasis.

Outcomes

Primary Outcomes

the prevalence of Paraneoplastic Syndrome in cirrhotic Patients with HCC.

Time Frame: 12 months

To investigate the prevalence of PNS (hypoglycemia, hypercholesterolemia, hypercalcemia, erythrocytosis, and thrombocytosis) and clinical characteristics in cirrhotic Patients with HCC.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Hala Maher Abdelhafiz

resident of Tropical department

Sohag University

Study Sites (1)

Loading locations...

Similar Trials